FDA Approves First-Line Panitumumab for RAS Wild-Type mCRC

June 30, 2017 – The FDA has approved panitumumab in combination with FOLFOX as a frontline treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC), according to Amgen, the company marketing the anti-EGFR antibody. In addition to the frontline approval, the agency also cleared panitumumab as a monotherapy for RAS wild-type mCRC following prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. For … (leggi tutto)